Clinical Trial

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Name: A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma — clinical trial record (NCT07562022)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular lymphoma (FL).

Protocol Amendment History 1 change

critical Recruitment opened 2026-08-14

Trial Details

NCT Number	NCT07562022
Lead Sponsor	Sinocelltech Ltd.
Conditions	Follicular Lymphoma (FL)
Enrollment	93 participants
Start Date	2026-06-09
Primary Completion	2028-05 (estimated)
Study Completion	2029-06 (estimated)
Updated on ClinicalTrials.gov	2026-08-13